Biotech Cash Runway Analysis
How to Calculate Months of Cash Remaining
Cash runway is the most important financial metric in biotech investing. When a pre-revenue company's cash drops below 12 months of operating expenses, dilutive financing becomes nearly inevitable. Here's exactly how to calculate runway, read the warning signs, and protect your portfolio from surprise stock offerings.
- Why Cash Runway Matters More Than Revenue
- The Cash Runway Formula: Step by Step
- Finding the Numbers in SEC Filings
- Interpreting Runway Levels: Safe, Warning, and Danger Zones
- The Going Concern Warning
- How Low Runway Triggers Dilution
- Real-World Examples: Cash Crises in Biotech
- Burn Rate Acceleration: The Hidden Trap
- Using BiotechSigns to Monitor Runway
- FAQ
Why Cash Runway Matters More Than Revenue
Unlike companies in most industries, the majority of publicly traded biotech companies have zero revenue. Of the roughly 800+ biotech companies listed on U.S. exchanges, approximately 70% are pre-revenue, meaning they have no approved products generating sales. Their entire existence depends on capital raised from investors to fund drug development.
This creates a fundamentally different financial dynamic. For a software company, you analyze revenue growth and profit margins. For a pre-revenue biotech, the most critical question is much simpler: how many months of cash does the company have left?
Cash runway directly determines whether a company can reach its next clinical milestone without needing to raise more capital. If a company is 8 months from a Phase 3 readout but only has 6 months of cash, shareholders face a near-certainty of dilutive financing before the catalyst arrives. Understanding this math is the single most important skill in biotech investing.
For pre-revenue biotech companies, cash runway is more important than any other financial metric. It tells you whether the company can survive long enough to reach its next value-creating catalyst, or whether it will need to dilute shareholders first.
The Cash Runway Formula: Step by Step
The basic formula is straightforward:
But getting accurate numbers requires knowing exactly where to look and what to include:
Step 1: Calculate Total Cash Position
From the balance sheet (found in 10-Q quarterly or 10-K annual filings), add together:
- Cash and cash equivalents — money in bank accounts and money market funds
- Short-term investments / marketable securities — Treasury bills, commercial paper, corporate bonds maturing within 12 months
- Restricted cash (if unrestricted) — some companies hold restricted cash for lease deposits or regulatory requirements; only include if it's available for operations
Do not include: long-term investments (may not be easily liquidated), accounts receivable (often negligible for pre-revenue biotechs), or the shelf registration capacity (that's potential future dilution, not current cash).
Step 2: Calculate Monthly Burn Rate
From the statement of cash flows, find net cash used in operating activities for the most recent quarter. Divide by 3 to get monthly burn rate.
Why operating cash flows instead of net loss? Because net loss includes large non-cash items like stock-based compensation (often $5-15M/quarter for mid-stage biotechs), depreciation, and amortization. These charges reduce reported earnings but do not consume actual cash. The cash flow statement strips these out and shows you the real cash going out the door.
Example: A company reports a net loss of $40M for Q1 but only used $28M in operating cash flows. The difference is $12M in non-cash stock compensation. Monthly burn rate = $28M / 3 = $9.3M per month.
Step 3: Divide and Interpret
If the company has $120M in total cash and burns $9.3M/month, the runway is 120 / 9.3 = 12.9 months. That puts it right at the edge of the warning zone.
Finding the Numbers in SEC Filings
Every publicly traded biotech files quarterly (10-Q) and annual (10-K) reports with the SEC. Here is exactly where to find the cash runway data:
Balance Sheet: Cash Position
Navigate to the filing on SEC EDGAR and find the Condensed Consolidated Balance Sheets. Look for the current assets section at the top. You want:
- Cash and cash equivalents
- Short-term investments (or marketable securities)
Add these together for your total cash figure. Compare to the prior quarter to see if the cash position is shrinking (it almost always is for pre-revenue biotechs).
Cash Flow Statement: Burn Rate
Find the Condensed Consolidated Statements of Cash Flows. The key line item is Net cash used in operating activities (it will be negative, shown in parentheses). This number represents actual cash consumed by the business during the quarter.
MD&A: Management's Own Assessment
The Management's Discussion and Analysis (MD&A) section contains a liquidity discussion where management is required to disclose whether they believe they have sufficient capital to fund operations for at least 12 months from the filing date. This is legally binding disclosure. If management says they do not have 12 months of runway, they must include a "going concern" disclosure, which triggers additional auditor warnings.
Interpreting Runway Levels: Safe, Warning, and Danger Zones
The Going Concern Warning
When a company's auditors (in the annual 10-K) or management (in quarterly 10-Q) determine that substantial doubt exists about the company's ability to continue as a going concern, they must disclose this in the filing. Under ASC 205-40, management must evaluate whether conditions exist that raise substantial doubt about the entity's ability to continue as a going concern for one year from the financial statement date.
A going concern warning is one of the strongest negative signals in biotech investing. It means the company's own accountants and management are telling you the company may not survive. Historically, biotechs with going concern warnings have a significantly higher rate of reverse splits, deeply dilutive financings, and eventual delisting.
You can search for going concern language by looking for phrases like "substantial doubt," "going concern," or "ability to continue" in the 10-Q or 10-K filing. BiotechSigns tracks these disclosures automatically as part of the biotech screener dilution risk assessment.
How Low Runway Triggers Dilution
When a pre-revenue biotech runs low on cash, it has limited options. Here are the most common financing mechanisms, ranked from least to most dilutive:
- At-the-Market (ATM) Offering: The company sells shares gradually on the open market through a broker. Less concentrated dilution, but creates persistent selling pressure. The company files a prospectus supplement (424B5) to establish the ATM facility, often for $50M-$200M.
- Follow-On Public Offering: A traditional underwritten offering where shares are sold at a fixed price, usually at a 5-15% discount to market. Dilution happens all at once, and the stock typically drops on the announcement. Filing: S-1 or 424B5 off an existing S-3 shelf.
- Private Placement (PIPE): Shares are sold directly to institutional investors, usually at a discount to market and often with attached warrants. The warrants create additional future dilution. These are common for smaller biotechs that cannot easily access public markets.
- Convertible Notes: The company issues debt that converts to equity at a later date, usually at a discount to the stock price at conversion. If the stock drops, conversion creates more shares (more dilution). Some convertible notes have "death spiral" provisions where the conversion price resets downward.
- Registered Direct Offering with Warrants: Similar to a PIPE but with registered shares. Typically done at a significant discount with warrants at or near the offering price. Creates immediate dilution from the shares plus future dilution from warrant exercise.
Track real-time dilution events across the biotech sector on DilutionWatch, which monitors SEC filings for shelf registrations, prospectus supplements, and warrant exercises as they happen.
Companies with less than 12 months of cash runway have historically underperformed the broader biotech sector by a significant margin. Dilutive financings destroy shareholder value through both share dilution and negative price signaling. Always verify cash runway before initiating a position in any pre-revenue biotech. Nothing in this guide is investment advice.
Real-World Examples: Cash Crises in Biotech
Understanding cash runway in theory is useful, but seeing how it plays out in practice is essential. Here are patterns that repeat across the sector:
The Pre-Catalyst Offering
A company has a Phase 3 readout in 9 months but only 7 months of cash. They announce an offering 3 months before the data readout, diluting shareholders at the worst possible time. The stock drops 20-30% on the offering, then may recover if data is positive. Investors who didn't calculate runway are caught off guard.
Companies like AGEN and APLS have demonstrated this pattern repeatedly in the clinical-stage biotech space. Checking whether a company can fund operations through its next major catalyst is the first thing experienced biotech investors do.
The Serial Diluter
Some companies develop a pattern of raising small amounts of capital every few months, never building a meaningful cash buffer. Each offering is a small percentage of market cap, but over 12-24 months, the cumulative dilution can reach 50-100%+ of the original share count. The stock chart shows a slow, steady decline punctuated by offering-day drops. These companies often have high executive compensation relative to market cap and limited clinical progress.
The Midnight PIPE
The company has been quiet about its financial situation. After the market closes on a Friday, they announce a private placement at a 25% discount to the closing price with full warrant coverage. Shareholders wake up Monday to a stock trading at 30-40% below Friday's close. This is most common with companies under $500M market cap that have less than 6 months of runway.
Burn Rate Acceleration: The Hidden Trap
One of the most common mistakes in runway analysis is assuming a constant burn rate. In reality, biotech burn rates frequently accelerate as companies advance through clinical development:
- Phase 1 to Phase 2: Burn rate typically increases 50-100% as trials expand to more patients and more sites
- Phase 2 to Phase 3: Burn rate can double or triple. Phase 3 trials involve hundreds to thousands of patients across dozens of clinical sites globally, requiring massive site management, data monitoring, and drug manufacturing expenses
- Pre-commercialization: If approval is expected, the company begins hiring a sales force, building manufacturing capacity, and launching marketing efforts months before the PDUFA date. This can add $10-30M/quarter to the burn rate
- Milestone payments: Licensing agreements often include development milestone payments ($5-20M) that create one-time spikes in cash outflow
Always compare the last 2-3 quarters of operating cash flow to see if burn rate is stable, increasing, or decreasing. If burn rate increased 20% last quarter and you use the old rate for your runway calculation, you'll overestimate runway by months.
Always look at the trend in burn rate over the last 2-3 quarters, not just the most recent quarter. A company entering Phase 3 will almost certainly see its burn rate increase substantially, shortening the actual runway compared to a naive calculation.
Using BiotechSigns to Monitor Runway
Manually calculating cash runway for every biotech position is time-consuming. BiotechSigns automates this analysis across 8,000+ biotech companies by tracking quarterly SEC filings and computing estimated runway in real time.
- Dilution Risk Scores — the BiotechSigns Screener grades every company on dilution risk, factoring in cash runway, recent offering history, shelf registration status, and outstanding warrants
- Real-time SEC monitoring — get alerts when companies file S-3 shelf registrations, 424B5 prospectus supplements, or 8-K announcements of new financings
- Cross-platform tracking — combine BiotechSigns cash runway data with DilutionWatch for real-time dilution event monitoring and StonkWhisper for institutional convergence signals
BiotechSigns tracks dilution risk, cash runway, and SEC filings across 8,000+ biotech companies. Filter by runway level to find companies at risk or those with ample funding.